Anita A Turk (Anita Turk)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 3

Top Topics

Metastatic Colorectal Cancer

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Hanna K Sanoff, Allision M Deal, Jai Patel, Jonathan D Sorah, Jacquelyne Gaddy, Bert O'Neil, Anita A Turk, William Irvin, Jeremiah Boles, Michael S Lee, Autumn McRee, Alexis C Wardell, Karen E Weck, Ethan M Basch, William A Wood, Federico Innocenti
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer. The oncologist (2024)
Hanna K Sanoff, Allision M Deal, Jai Patel, Jonathan D Sorah, Jacquelyne Gaddy, Bert O'Neil, Anita A Turk, William Irvin, Jeremiah Boles, Michael S Lee, Autumn McRee, Alexis C Wardell, Karen E Weck, Ethan M Basch, William A Wood, Federico Innocenti
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer. The oncologist (2024)
Maitri Kalra, Elizabeth Henry, Kelly E McCann, Meghan S Karuturi, Jean G Bustamante Alvarez, Amanda Parkes, Robert Wesolowski, Mei Wei, Sarah S Mougalian, Gregory Durm, Angel Qin, Caitlin A Schonewolf, Meghna S Trivedi, Avan J Armaghani, Frederick H Wilson, Wade T Iams, Anita A Turk, Praveen Vikas, Michael Cecchini, Sam Lubner, Priyadarshini Pathak, Kristen Spencer, Vadim S Koshkin, Matthew Kyle Labriola, Catherine Handy Marshall, Kathryn E Beckermann, null null, Marina N Sharifi, Anthony C Bejjani, Varsha Hotchandani, Samir Housri, Nadine Housri
Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR cancer 8 (2) (2022)